Microvascular Therapeutics is a clinical stage biopharma company pioneering in ultrasound contrast agents and theranostics. The company is further advancing a Phase I/II asset (MVT-100) for echocardiography through the 505(B)(2) regulatory path. The next follow-on product, MVT-101, regulated as a device, is finishing late-preclinical GLP studies for deep vein thrombosis and pulmonary emboli indications. Finally, several preclinical programs are moving forward for other products for early detection and treatment of cancers such as brain tumor and pancreatic cancer.